Search

Your search keyword '"Oberstein, Paul E."' showing total 41 results
Start Over Author "Oberstein, Paul E." Publication Year Range Last 10 years
41 results on '"Oberstein, Paul E."'

1. Altered salivary microbiota associated with high-sugar beverage consumption.

Author

Fan, Xiaozhou, Monson, Kelsey R., Peters, Brandilyn A., Whittington, Jennifer M., Um, Caroline Y., Oberstein, Paul E., McCullough, Marjorie L., Freedman, Neal D., Huang, Wen-Yi, Ahn, Jiyoung, and Hayes, Richard B.

Subjects
BEVERAGE consumption, SUGAR content of beverages, HUMAN microbiota, LACTOBACILLUS rhamnosus, DENTAL plaque, BEVERAGES
Abstract

The human oral microbiome may alter oral and systemic disease risk. Consuming high sugar content beverages (HSB) can lead to caries development by altering the microbial composition in dental plaque, but little is known regarding HSB-specific oral microbial alterations. Therefore, we conducted a large, population-based study to examine associations of HSB intake with oral microbiome diversity and composition. Using mouthwash samples of 989 individuals in two nationwide U.S. cohorts, bacterial 16S rRNA genes were amplified, sequenced, and assigned to bacterial taxa. HSB intake was quantified from food frequency questionnaires as low (< 1 serving/week), medium (1–3 servings/week), or high (> 3 servings/week). We assessed overall bacterial diversity and presence of specific taxa with respect to HSB intake in each cohort separately and combined in a meta-analysis. Consistently in the two cohorts, we found lower species richness in high HSB consumers (> 3 cans/week) (p = 0.027), and that overall bacterial community profiles differed from those of non-consumers (PERMANOVA p = 0.040). Specifically, presence of a network of commensal bacteria (Lachnospiraceae, Peptostreptococcaceae, and Alloprevotella rava) was less common in high compared to non-consumers, as were other species including Campylobacter showae, Prevotella oulorum, and Mycoplasma faucium. Presence of acidogenic bacteria Bifodobacteriaceae and Lactobacillus rhamnosus was more common in high consumers. Abundance of Fusobacteriales and its genus Leptotrichia, Lachnoanaerobaculum sp., and Campylobacter were lower with higher HSB consumption, and their abundances were correlated. No significant interaction was found for these associations with diabetic status or with microbial markers for caries (S. mutans) and periodontitis (P. gingivalis). Our results suggest that soft drink intake may alter the salivary microbiota, with consistent results across two independent cohorts. The observed perturbations of overrepresented acidogenic bacteria and underrepresented commensal bacteria in high HSB consumers may have implications for oral and systemic disease risk. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Data from Cholinergic Signaling via Muscarinic Receptors Directly and Indirectly Suppresses Pancreatic Tumorigenesis and Cancer Stemness

Author

Renz, Bernhard W., primary, Tanaka, Takayuki, primary, Sunagawa, Masaki, primary, Takahashi, Ryota, primary, Jiang, Zhengyu, primary, Macchini, Marina, primary, Dantes, Zahra, primary, Valenti, Giovanni, primary, White, Ruth A., primary, Middelhoff, Moritz A., primary, Ilmer, Matthias, primary, Oberstein, Paul E., primary, Angele, Martin K., primary, Deng, Huan, primary, Hayakawa, Yoku, primary, Westphalen, C. Benedikt, primary, Werner, Jens, primary, Remotti, Helen, primary, Reichert, Maximilian, primary, Tailor, Yagnesh H., primary, Nagar, Karan, primary, Friedman, Richard A., primary, Iuga, Alina C., primary, Olive, Kenneth P., primary, and Wang, Timothy C., primary

Published
2023
Full Text
View/download PDF

7. Supplementary Data from Cholinergic Signaling via Muscarinic Receptors Directly and Indirectly Suppresses Pancreatic Tumorigenesis and Cancer Stemness

Author

Renz, Bernhard W., primary, Tanaka, Takayuki, primary, Sunagawa, Masaki, primary, Takahashi, Ryota, primary, Jiang, Zhengyu, primary, Macchini, Marina, primary, Dantes, Zahra, primary, Valenti, Giovanni, primary, White, Ruth A., primary, Middelhoff, Moritz A., primary, Ilmer, Matthias, primary, Oberstein, Paul E., primary, Angele, Martin K., primary, Deng, Huan, primary, Hayakawa, Yoku, primary, Westphalen, C. Benedikt, primary, Werner, Jens, primary, Remotti, Helen, primary, Reichert, Maximilian, primary, Tailor, Yagnesh H., primary, Nagar, Karan, primary, Friedman, Richard A., primary, Iuga, Alina C., primary, Olive, Kenneth P., primary, and Wang, Timothy C., primary

Published
2023
Full Text
View/download PDF

8. Figure S3 from Harmonic Motion Imaging of Pancreatic Tumor Stiffness Indicates Disease State and Treatment Response

Author

Payen, Thomas, primary, Oberstein, Paul E., primary, Saharkhiz, Niloufar, primary, Palermo, Carmine F., primary, Sastra, Stephen A., primary, Han, Yang, primary, Nabavizadeh, Alireza, primary, Sagalovskiy, Irina R., primary, Orelli, Barbara, primary, Rosario, Vilma, primary, Desrouilleres, Deborah, primary, Remotti, Helen, primary, Kluger, Michael D., primary, Schrope, Beth A., primary, Chabot, John A., primary, Iuga, Alina C., primary, Konofagou, Elisa E., primary, and Olive, Kenneth P., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Data from Harmonic Motion Imaging of Pancreatic Tumor Stiffness Indicates Disease State and Treatment Response

Author

Payen, Thomas, primary, Oberstein, Paul E., primary, Saharkhiz, Niloufar, primary, Palermo, Carmine F., primary, Sastra, Stephen A., primary, Han, Yang, primary, Nabavizadeh, Alireza, primary, Sagalovskiy, Irina R., primary, Orelli, Barbara, primary, Rosario, Vilma, primary, Desrouilleres, Deborah, primary, Remotti, Helen, primary, Kluger, Michael D., primary, Schrope, Beth A., primary, Chabot, John A., primary, Iuga, Alina C., primary, Konofagou, Elisa E., primary, and Olive, Kenneth P., primary

Published
2023
Full Text
View/download PDF

10. Corrigendum: Tumor infiltrating T cell states and checkpoint inhibitor expression in hepatic and pancreatic malignancies

Author

Wan, Shanshan, primary, Zhao, Ende, additional, Freeman, Daniel, additional, Weissinger, Daniel, additional, Krantz, Benjamin A., additional, Werba, Gregor, additional, Khanna, Lauren G., additional, Siolas, Despina, additional, Oberstein, Paul E., additional, Chattopadhyay, Pratip K., additional, Simeone, Diane M., additional, and Welling, Theodore H., additional

Published
2023
Full Text
View/download PDF

11. Tumor infiltrating T cell states and checkpoint inhibitor expression in hepatic and pancreatic malignancies

Author

Wan, Shanshan, primary, Zhao, Ende, additional, Weissinger, Daniel, additional, Krantz, Benjamin A., additional, Werba, Gregor, additional, Freeman, Daniel, additional, Khanna, Lauren G., additional, Siolas, Despina, additional, Oberstein, Paul E., additional, Chattopadhyay, Pratip K., additional, Simeone, Diane M., additional, and Welling, Theodore H., additional

Published
2023
Full Text
View/download PDF

13. Reply to ‘H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines’

Author

Alvarez, Mariano J., Yan, Pengrong, Alpaugh, Mary L., Bowden, Michaela, Sicinska, Ewa, Zhou, Chensheng W., Karan, Charles, Realubit, Ronald B., Mundi, Prabhjot S., Grunn, Adina, Jäger, Dirk, Chabot, John A., Fojo, Antonio T., Oberstein, Paul E., Hibshoosh, Hanina, Milsom, Jeffrey W., Kulke, Matthew H., Loda, Massimo, Chiosis, Gabriela, Reidy-Lagunes, Diane L., and Califano, Andrea

Published
2019
Full Text
View/download PDF

14. Abstract PR010: Single-cell sequencing elucidates the effects of chemotherapy on cancer cell heterogeneity and the tumor microenvironment of human pancreatic adenocarcinoma

Author

Weissinger, Daniel, primary, Kawaler, Emily A., additional, Werba, Gregor, additional, Zhao, Ende, additional, Kalfakakou, Despoina, additional, Dhara, Surajit, additional, Oh, Grace, additional, Jing, Xiaohong, additional, Beri, Nina, additional, Khanna, Lauren, additional, Gonda, Tamas, additional, Oberstein, Paul E., additional, Hajdu, Cristina, additional, Loomis, Cynthia, additional, Heguy, Adriana, additional, Sherman, Mara H., additional, Lund, Amanda W., additional, Welling, Theodore H., additional, Dolgalev, Igor, additional, Tsirigos, Aristotelis, additional, and Simeone, Diane M., additional

Published
2022
Full Text
View/download PDF

15. Abstract PR005: Primary results of PanCAN-SR1, a phase 1b study evaluating Gemcitabine, nab-Paclitaxel, Canakinumab, and Spartalizumab to target IL-1β and PD-1 in metastatic pancreatic cancer with correlative tissue and blood biomarker analysis

Author

Oberstein, Paul E., primary, Rahma, Osama, additional, Beri, Nina, additional, Stoll-D'Astice, Amy, additional, Kawaler, Emily A., additional, Dolgalev, Igor, additional, Werba, Gregor, additional, Cardo-Ruffino, Victoire, additional, Böllenrücher, Naïma, additional, Costa, Andressa Dias, additional, Nazeer, Saloney, additional, Squires, Matthew, additional, Nowak, Jonathan, additional, Bar-Sagi, Dafna, additional, Wolpin, Brian, additional, Simeone, Diane M, additional, and Dougan, Stephanie K, additional

Published
2022
Full Text
View/download PDF

16. Impact of comprehensive family history and genetic analysis in the multidisciplinary pancreatic tumor clinic setting

Author

Everett, Jessica N., primary, Dettwyler, Shenin A., additional, Jing, Xiaohong, additional, Stender, Cody, additional, Schmitter, Madeleine, additional, Baptiste, Ariele, additional, Chun, Jennifer, additional, Kawaler, Emily A., additional, Khanna, Lauren G., additional, Gross, Seth A., additional, Gonda, Tamas A., additional, Beri, Nina, additional, Oberstein, Paul E., additional, and Simeone, Diane M., additional

Published
2022
Full Text
View/download PDF

18. Multiplexed single-cell analysis reveals prognostic and nonprognostic T cell types in human colorectal cancer

Author

Masuda, Kazuya, primary, Kornberg, Adam, additional, Miller, Jonathan, additional, Lin, Sijie, additional, Suek, Nathan, additional, Botella, Theo, additional, Secener, Kerim A., additional, Bacarella, Alyssa M., additional, Cheng, Liang, additional, Ingham, Matthew, additional, Rosario, Vilma, additional, Al-Mazrou, Ahmed M., additional, Lee-Kong, Steven A., additional, Kiran, Ravi P., additional, Stoeckius, Marlon, additional, Smibert, Peter, additional, Del Portillo, Armando, additional, Oberstein, Paul E., additional, Sims, Peter A., additional, Yan, Kelley S., additional, and Han, Arnold, additional

Published
2022
Full Text
View/download PDF

19. Impact of comprehensive family history and genetic analysis in the multidisciplinary pancreatic tumor clinic setting.

Author

Everett, Jessica N., Dettwyler, Shenin A., Jing, Xiaohong, Stender, Cody, Schmitter, Madeleine, Baptiste, Ariele, Chun, Jennifer, Kawaler, Emily A., Khanna, Lauren G., Gross, Seth A., Gonda, Tamas A., Beri, Nina, Oberstein, Paul E., and Simeone, Diane M.

Subjects
PANCREATIC tumors, GENETIC testing, INTERDISCIPLINARY research, FAMILY history (Medicine), CONTINUUM of care, PANCREATIC duct, HEREDITARY cancer syndromes
Abstract

Background: Genetic testing is recommended for all pancreatic ductal adenocarcinoma (PDAC) patients. Prior research demonstrates that multidisciplinary pancreatic cancer clinics (MDPCs) improve treatment‐ and survival‐related outcomes for PDAC patients. However, limited information exists regarding the utility of integrated genetics in the MDPC setting. We hypothesized that incorporating genetics in an MDPC serving both PDAC patients and high‐risk individuals (HRI) could: (1) improve compliance with guideline‐based genetic testing for PDAC patients, and (2) optimize HRI identification and PDAC surveillance participation to improve early detection and survival. Methods: Demographics, genetic testing results, and pedigrees were reviewed for PDAC patients and HRI at one institution over 45 months. Genetic testing analyzed 16 PDAC‐associated genes at minimum. Results: Overall, 969 MDPC subjects were evaluated during the study period; another 56 PDAC patients were seen outside the MDPC. Among 425 MDPC PDAC patients, 333 (78.4%) completed genetic testing; 29 (8.7%) carried a PDAC‐related pathogenic germline variant (PGV). Additionally, 32 (9.6%) met familial pancreatic cancer (FPC) criteria. These PDAC patients had 191 relatives eligible for surveillance or genetic testing. Only 2/56 (3.6%) non‐MDPC PDAC patients completed genetic testing (p < 0.01). Among 544 HRI, 253 (46.5%) had a known PGV or a designation of FPC, and were eligible for surveillance at baseline; of the remainder, 15/291 (5.2%) were eligible following genetic testing and PGV identification. Conclusion: Integrating genetics into the multidisciplinary setting significantly improved genetic testing compliance by reducing logistical barriers for PDAC patients, and clarified cancer risks for their relatives while conserving clinical resources. Overall, we identified 206 individuals newly eligible for surveillance or genetic testing (191 relatives of MDPC PDAC patients, and 15 HRI from this cohort), enabling continuity of care for PDAC patients and at‐risk relatives in one clinic. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

20. Tumor infiltrating T cell states and checkpoint inhibitor expression in hepatic and pancreatic malignancies.

Author

Shanshan Wan, Ende Zhao, Weissinger, Daniel, Krantz, Benjamin A., Werba, Gregor, Freeman, Daniel, Khanna, Lauren G., Siolas, Despina, Oberstein, Paul E., Chattopadhyay, Pratip K., Simeone, Diane M., and Welling, Theodore H.

Subjects
T cells, IPILIMUMAB, PANCREATIC tumors, PANCREATIC duct, CANCER chemotherapy, IMMUNOLOGIC memory, IMMUNE checkpoint proteins
Abstract

Hepato-pancreatico-biliary (HPB) malignancies are difficult-to-treat and continue to to have a high mortality and significant therapeutic resistance to standard therapies. Immune oncology (IO) therapies have demonstrated efficacy in several solid malignancies when combined with chemotherapy, whereas response rates in pancreatic ductal adenocarcinoma (PDA) are poor. While promising in hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), there remains an unmet need to fully leverage IO therapies to treat HPB tumors. We therefore defined T cell subsets in the tumor microenvironment of HPB patients utilizing a novel, multiparameter flow cytometry and bioinformatics analysis. Our findings quantify the T cell phenotypic states in relation to checkpoint receptor expression. We demonstrate the presence of CD103+ tissue resident memory T cells (TRM), CCR7+ central memory T cells, and CD57+ terminally differentiated effector cells across all HPB cancers, while the anti-tumor function was dampened by expression of multiple co-inhibitory checkpoint receptors. Terminally exhausted T cells lacking co-stimulatory receptors were more prevalent in PDA, whereas partially exhausted T cells expressing both co-inhibitory and co-stimulatory receptors were most prevalent in HCC, especially in early stage. HCC patients had significantly higher TRM with a phenotype that could confer restored activation in response to immune checkpoint therapies. Further, we found a lack of robust alteration in T cell activation state or checkpoint expression in response to chemotherapy in PDA patients. These results support that HCC patients might benefit most from combined checkpoint therapies, whereas efforts other than cytotoxic chemotherapy will likely be necessary to increase overall T cell activation in CCA and PDA for future clinical development. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. The functional and phenotypic diversity of single T-cell infiltrates in human colorectal cancer as correlated with clinical outcome

Author

Masuda, Kazuya, primary, Kornberg, Adam, additional, Lin, Sijie, additional, Ho, Patricia, additional, Secener, Kerim, additional, Suek, Nathan, additional, Bacarella, Alyssa M., additional, Ingham, Matthew, additional, Rosario, Vilma, additional, Al-Masrou, Ahmed M., additional, Lee-Kong, Steven A., additional, Kiran, P. Ravi, additional, Yan, Kelley S., additional, Stoeckius, Marlon, additional, Smibert, Peter, additional, Oberstein, Paul E., additional, Sims, Peter A., additional, and Han, Arnold, additional

Published
2020
Full Text
View/download PDF

25. Abstract LB-003: OncoMatch: Unbiased, quantitative assessment of cancer model fidelity for drug sensitivity and mechanism of action elucidation

Author

Alvarez, Mariano J., primary, Pengrong, Yan, additional, Alpaugh, Mary L., additional, Bowden, Michaela, additional, Sicinska, Ewa T., additional, Zhou, Chensheng W., additional, Karan, Charles, additional, Realubit, Ronald B., additional, Mundi, Prabhjot S., additional, Grunn, Adina, additional, Dirk, Jager, additional, Chabot, John A., additional, Fojo, Antonio T., additional, Oberstein, Paul E., additional, Hibshoosh, Hanina, additional, Milsom, Jeffrey W., additional, Kulke, Matthew H., additional, Loda, Massimo, additional, Chiosis, Gabriela, additional, Reidy-Lagunes, Diane L., additional, and Califano, Andrea, additional

Published
2020
Full Text
View/download PDF

27. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Author

Kuderer, Nicole M, primary, Choueiri, Toni K, additional, Shah, Dimpy P, additional, Shyr, Yu, additional, Rubinstein, Samuel M, additional, Rivera, Donna R, additional, Shete, Sanjay, additional, Hsu, Chih-Yuan, additional, Desai, Aakash, additional, de Lima Lopes, Gilberto, additional, Grivas, Petros, additional, Painter, Corrie A, additional, Peters, Solange, additional, Thompson, Michael A, additional, Bakouny, Ziad, additional, Batist, Gerald, additional, Bekaii-Saab, Tanios, additional, Bilen, Mehmet A, additional, Bouganim, Nathaniel, additional, Larroya, Mateo Bover, additional, Castellano, Daniel, additional, Del Prete, Salvatore A, additional, Doroshow, Deborah B, additional, Egan, Pamela C, additional, Elkrief, Arielle, additional, Farmakiotis, Dimitrios, additional, Flora, Daniel, additional, Galsky, Matthew D, additional, Glover, Michael J, additional, Griffiths, Elizabeth A, additional, Gulati, Anthony P, additional, Gupta, Shilpa, additional, Hafez, Navid, additional, Halfdanarson, Thorvardur R, additional, Hawley, Jessica E, additional, Hsu, Emily, additional, Kasi, Anup, additional, Khaki, Ali R, additional, Lemmon, Christopher A, additional, Lewis, Colleen, additional, Logan, Barbara, additional, Masters, Tyler, additional, McKay, Rana R, additional, Mesa, Ruben A, additional, Morgans, Alicia K, additional, Mulcahy, Mary F, additional, Panagiotou, Orestis A, additional, Peddi, Prakash, additional, Pennell, Nathan A, additional, Reynolds, Kerry, additional, Rosen, Lane R, additional, Rosovsky, Rachel, additional, Salazar, Mary, additional, Schmidt, Andrew, additional, Shah, Sumit A, additional, Shaya, Justin A, additional, Steinharter, John, additional, Stockerl-Goldstein, Keith E, additional, Subbiah, Suki, additional, Vinh, Donald C, additional, Wehbe, Firas H, additional, Weissmann, Lisa B, additional, Wu, Julie Tsu-Yu, additional, Wulff-Burchfield, Elizabeth, additional, Xie, Zhuoer, additional, Yeh, Albert, additional, Yu, Peter P, additional, Zhou, Alice Y, additional, Zubiri, Leyre, additional, Mishra, Sanjay, additional, Lyman, Gary H, additional, Rini, Brian I, additional, Warner, Jeremy L, additional, Abidi, Maheen, additional, Acoba, Jared D., additional, Agarwal, Neeraj, additional, Ahmad, Syed, additional, Ajmera, Archana, additional, Altman, Jessica, additional, Angevine, Anne H., additional, Azad, Nilo, additional, Bar, Michael H., additional, Bardia, Aditya, additional, Barnholtz-Sloan, Jill, additional, Barrow, Briana, additional, Bashir, Babar, additional, Belenkaya, Rimma, additional, Berg, Stephanie, additional, Bernicker, Eric H., additional, Bestvina, Christine, additional, Bishnoi, Rohit, additional, Boland, Genevieve, additional, Bonnen, Mark, additional, Bouchard, Gabrielle, additional, Bowles, Daniel W., additional, Busser, Fiona, additional, Cabal, Angelo, additional, Caimi, Paolo, additional, Carducci, Theresa, additional, Casulo, Carla, additional, Chen, James L., additional, Clement, Jessica M, additional, Chism, David, additional, Cook, Erin, additional, Curran, Catherine, additional, Daher, Ahmad, additional, Dailey, Mark, additional, Dahiya, Saurabh, additional, Deeken, John, additional, Demetri, George D., additional, DiLullo, Sandy, additional, Duma, Narjust, additional, Elias, Rawad, additional, Faller, Bryan, additional, Fecher, Leslie A., additional, Feldman, Lawrence E., additional, Friese, Christopher R., additional, Fu, Paul, additional, Fu, Julie, additional, Futreal, Andy, additional, Gainor, Justin, additional, Garcia, Jorge, additional, Gill, David M., additional, Gillaspie, Erin A., additional, Giordano, Antonio, additional, Glace, (Mary) Grace, additional, Grothey, Axel, additional, Gulati, Shuchi, additional, Gurley, Michael, additional, Halmos, Balazs, additional, Herbst, Roy, additional, Hershman, Dawn, additional, Hoskins, Kent, additional, Jain, Rohit K., additional, Jabbour, Salma, additional, Jha, Alokkumar, additional, Johnson, Douglas B., additional, Joshi, Monika, additional, Kelleher, Kaitlin, additional, Kharofa, Jordan, additional, Khan, Hina, additional, Knoble, Jeanna, additional, Koshkin, Vadim S., additional, Kulkarni, Amit A., additional, Lammers, Philip E., additional, Leighton, John C., additional, Lewis, Mark A., additional, Li, Xuanyi, additional, Li, Ang, additional, Lo, K.M. Steve, additional, Loaiza-Bonilla, Arturo, additional, LoRusso, Patricia, additional, Low, Clarke A., additional, Lustberg, Maryam B., additional, Mahadevan, Daruka, additional, Mansoor, Abdul-Hai, additional, Marcum, Michelle, additional, Markham, Merry Jennifer, additional, Handy Marshall, Catherine, additional, Mashru, Sandeep H., additional, Matar, Sara, additional, McNair, Christopher, additional, McWeeney, Shannon, additional, Mehnert, Janice M., additional, Menendez, Alvaro, additional, Menon, Harry, additional, Messmer, Marcus, additional, Monahan, Ryan, additional, Mushtaq, Sarah, additional, Nagaraj, Gayathri, additional, Nagle, Sarah, additional, Naidoo, Jarushka, additional, Nakayama, John M., additional, Narayan, Vikram, additional, Nelson, Heather H., additional, Nemecek, Eneida R., additional, Nguyen, Ryan, additional, Nuzzo, Pier Vitale, additional, Oberstein, Paul E., additional, Olszewski, Adam J., additional, Owenby, Susie, additional, Pasquinelli, Mary M., additional, Philip, John, additional, Prabhakaran, Sabitha, additional, Puc, Matthew, additional, Ramirez, Amelie, additional, Rathmann, Joerg, additional, Revankar, Sanjay G., additional, Rho, Young Soo, additional, Rhodes, Terence D., additional, Rice, Robert L., additional, Riely, Gregory J., additional, Riess, Jonathan, additional, Rink, Cameron, additional, Robilotti, Elizabeth V., additional, Rosenstein, Lori, additional, Routy, Bertrand, additional, Rovito, Marc A., additional, Saif, M. Wasif, additional, Sanyal, Amit, additional, Schapira, Lidia, additional, Schwartz, Candice, additional, Serrano, Oscar, additional, Shah, Mansi, additional, Shah, Chintan, additional, Shaw, Grace, additional, Shergill, Ardaman, additional, Shouse, Geoffrey, additional, Soares, Heloisa P., additional, Solorzano, Carmen C., additional, Srivastava, Pramod K., additional, Stauffer, Karen, additional, Stover, Daniel G., additional, Stratton, Jamie, additional, Stratton, Catherine, additional, Subbiah, Vivek, additional, Tamimi, Rulla, additional, Tannir, Nizar M., additional, Topaloglu, Umit, additional, Van Allen, Eli, additional, Van Loon, Susan, additional, Vega-Luna, Karen, additional, Venepalli, Neeta, additional, Verma, Amit K., additional, Vikas, Praveen, additional, Wall, Sarah, additional, Weinstein, Paul L., additional, Weiss, Matthias, additional, Wise-Draper, Trisha, additional, Wood, William A., additional, Xu, Wenxin (Vincent), additional, Yackzan, Susan, additional, Zacks, Rosemary, additional, Zhang, Tian, additional, Zimmer, Andrea J., additional, and West, Jack, additional

Published
2020
Full Text
View/download PDF

28. Harmonic Motion Imaging of Pancreatic Tumor Stiffness Indicates Disease State and Treatment Response

Author

Payen, Thomas, primary, Oberstein, Paul E., additional, Saharkhiz, Niloufar, additional, Palermo, Carmine F., additional, Sastra, Stephen A., additional, Han, Yang, additional, Nabavizadeh, Alireza, additional, Sagalovskiy, Irina R., additional, Orelli, Barbara, additional, Rosario, Vilma, additional, Desrouilleres, Deborah, additional, Remotti, Helen, additional, Kluger, Michael D., additional, Schrope, Beth A., additional, Chabot, John A., additional, Iuga, Alina C., additional, Konofagou, Elisa E., additional, and Olive, Kenneth P., additional

Published
2020
Full Text
View/download PDF

29. Noninvasive Young's modulus visualization of fibrosis progression and delineation of pancreatic ductal adenocarcinoma (PDAC) tumors using Harmonic Motion Elastography (HME) in vivo

Author

Nabavizadeh, Alireza, primary, Payen, Thomas, additional, Iuga, Alina C., additional, Sagalovskiy, Irina R., additional, Desrouilleres, Deborah, additional, Saharkhiz, Niloufar, additional, Palermo, Carmine F., additional, Sastra, Stephen A., additional, Oberstein, Paul E., additional, Rosario, Vilma, additional, Kluger, Michael D., additional, Schrope, Beth A., additional, Chabot, John A., additional, Olive, Kenneth P., additional, and Konofagou, Elisa E., additional

Published
2020
Full Text
View/download PDF

30. Unbiased Assessment of H-STS cells as high-fidelity models for gastro-enteropancreatic neuroendocrine tumor drug mechanism of action analysis

Author

Alvarez, Mariano J., primary, Yan, Pengrong, additional, Alpaugh, Mary L., additional, Bowden, Michaela, additional, Sicinska, Ewa, additional, Zhou, Chensheng W., additional, Karan, Charles, additional, Realubit, Ronald B., additional, Mundi, Prabhjot S., additional, Grunn, Adina, additional, Jäger, Dirk, additional, Chabot, John A., additional, Fojo, Antonio T., additional, Oberstein, Paul E., additional, Hibshoosh, Hanina, additional, Milsom, Jeffrey W., additional, Kulke, Matthew H., additional, Loda, Massimo, additional, Chiosis, Gabriela, additional, Reidy-Lagunes, Diane L., additional, and Califano, Andrea, additional

Published
2019
Full Text
View/download PDF

31. Cholinergic Signaling Directly and Indirectly Suppresses Pancreatic Tumorigenesis and Cancer Stemness

Author

Renz, Bernhard W., primary, Tanaka, Takayuki, additional, Sunagawa, Masaki, additional, Takahasi, Ryota, additional, Macchini, Marina, additional, Dantes, Zahra, additional, Valenti, Giovanni, additional, Ilmer, Matthias, additional, Westphalen, C. Benedikt, additional, Reichert, Maximilian, additional, Oberstein, Paul E., additional, Iuga, Alina C., additional, Werner, Jens, additional, Olive, Kenneth P., additional, and Wang, Timothy C., additional

Published
2019
Full Text
View/download PDF

32. Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes

Author

Maurer, Carlo, primary, Holmstrom, Sam R, additional, He, Jing, additional, Laise, Pasquale, additional, Su, Tao, additional, Ahmed, Aqeel, additional, Hibshoosh, Hanina, additional, Chabot, John A, additional, Oberstein, Paul E, additional, Sepulveda, Antonia R, additional, Genkinger, Jeanine M, additional, Zhang, Jiapeng, additional, Iuga, Alina C, additional, Bansal, Mukesh, additional, Califano, Andrea, additional, and Olive, Kenneth P, additional

Published
2019
Full Text
View/download PDF

33. Cholinergic Signaling via Muscarinic Receptors Directly and Indirectly Suppresses Pancreatic Tumorigenesis and Cancer Stemness

Author

Renz, Bernhard W., primary, Tanaka, Takayuki, additional, Sunagawa, Masaki, additional, Takahashi, Ryota, additional, Jiang, Zhengyu, additional, Macchini, Marina, additional, Dantes, Zahra, additional, Valenti, Giovanni, additional, White, Ruth A., additional, Middelhoff, Moritz A., additional, Ilmer, Matthias, additional, Oberstein, Paul E., additional, Angele, Martin K., additional, Deng, Huan, additional, Hayakawa, Yoku, additional, Westphalen, C. Benedikt, additional, Werner, Jens, additional, Remotti, Helen, additional, Reichert, Maximilian, additional, Tailor, Yagnesh H., additional, Nagar, Karan, additional, Friedman, Richard A., additional, Iuga, Alina C., additional, Olive, Kenneth P., additional, and Wang, Timothy C., additional

Published
2018
Full Text
View/download PDF

34. Parasympathetic signaling via Chrm1 directly suppresses pancreatic carcinogenesis and cancer stemness through inhibition of EGFR/MAPK and PI3K/AKT pathway

Author

Renz, Bernhard W., primary, Tanaka, Takayuki Tanaka, additional, Macchini, Marina, additional, Hayakawa, Yoku, additional, Ilmer, Matthias, additional, Takahashi, Ryota, additional, Westphalen, C. Benedikt, additional, Oberstein, Paul E., additional, Iuga, Alina C., additional, Friedmann, Richard A., additional, Werner, Jens, additional, Olive, Kenneth P., additional, and Wang, Timothy C., additional

Published
2018
Full Text
View/download PDF

35. Transcriptional deconvolution reveals consistent functional subtypes of pancreatic cancer epithelium and stroma

Author

He, Jing, primary, Maurer, H. Carlo, additional, Holmstrom, Sam R., additional, Su, Tao, additional, Ahmed, Aqeel, additional, Hibshoosh, Hanina, additional, Chabot, John A., additional, Oberstein, Paul E., additional, Sepulveda, Antonia R., additional, Genkinger, Jeanine M., additional, Zhang, Jiapeng, additional, Iuga, Alina C., additional, Califano, Andrea, additional, Bansal, Mukesh, additional, and Olive, Kenneth P., additional

Published
2018
Full Text
View/download PDF

36. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma

Author

Hingorani, Sunil R., primary, Zheng, Lei, additional, Bullock, Andrea J., additional, Seery, Tara E., additional, Harris, William P., additional, Sigal, Darren S., additional, Braiteh, Fadi, additional, Ritch, Paul S., additional, Zalupski, Mark M., additional, Bahary, Nathan, additional, Oberstein, Paul E., additional, Wang-Gillam, Andrea, additional, Wu, Wilson, additional, Chondros, Dimitrios, additional, Jiang, Ping, additional, Khelifa, Sihem, additional, Pu, Jie, additional, Aldrich, Carrie, additional, and Hendifar, Andrew E., additional

Published
2018
Full Text
View/download PDF

37. Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours

Author

Raymond, Eric, primary, Kulke, Matthew H., additional, Qin, Shukui, additional, Yu, Xianjun, additional, Schenker, Michael, additional, Cubillo, Antonio, additional, Lou, Wenhui, additional, Tomasek, Jiri, additional, Thiis-Evensen, Espen, additional, Xu, Jian-Ming, additional, Croitoru, Adina E., additional, Khasraw, Mustafa, additional, Sedlackova, Eva, additional, Borbath, Ivan, additional, Ruff, Paul, additional, Oberstein, Paul E., additional, Ito, Tetsuhide, additional, Jia, Liqun, additional, Hammel, Pascal, additional, Shen, Lin, additional, Shrikhande, Shailesh V., additional, Shen, Yali, additional, Sufliarsky, Jozef, additional, Khan, Gazala N., additional, Morizane, Chigusa, additional, Galdy, Salvatore, additional, Khosravan, Reza, additional, Fernandez, Kathrine C., additional, Rosbrook, Brad, additional, and Fazio, Nicola, additional

Published
2018
Full Text
View/download PDF

38. Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer

Author

Yarchoan, Mark, primary, Myzak, Melinda C., additional, Johnson, Burles A., additional, De Jesus-Acosta, Ana, additional, Le, Dung T., additional, Jaffee, Elizabeth M., additional, Azad, Nilofer S., additional, Donehower, Ross C., additional, Zheng, Lei, additional, Oberstein, Paul E., additional, Fine, Robert L., additional, Laheru, Daniel A., additional, and Goggins, Michael, additional

Published
2017
Full Text
View/download PDF

40. Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study.

Author

Philip PA, Sahai V, Bahary N, Mahipal A, Kasi A, Rocha Lima CMS, Alistar AT, Oberstein PE, Golan T, Metges JP, Lacy J, Fountzilas C, Lopez CD, Ducreux M, Hammel P, Salem M, Bajor D, Benson AB, Luther S, Pardee T, and Van Cutsem E

Abstract

Purpose: Metastatic pancreatic adenocarcinoma (mPC) remains a difficult-to-treat disease. Fluorouarcil, oxaliplatin, irinotecan, and leucovorin (FFX) is a standard first-line therapy for mPC for patients with a favorable performance status and good organ function. In a phase I study, devimistat (CPI-613) in combination with modified FFX (mFFX) was deemed safe and exhibited promising efficacy in mPC., Methods: The AVENGER 500 trial (ClinicalTrials.gov identifier: NCT03504423) is a global, randomized phase III trial conducted at 74 sites across six countries to investigate the efficacy and safety of devimistat in combination with mFFX (experimental arm) compared with standard-dose FFX (control arm) in treatment-naïve patients with mPC. Treatment, administered in once-every-2-weeks cycles until disease progression or intolerable toxicity, included intravenous devimistat at 500 mg/m 2 total per day on days 1 and 3 in the experimental arm. The primary end point of the study was overall survival (OS)., Results: Five hundred and twenty-eight patients were randomly assigned (266 in the experimental arm and 262 in the control arm). The median OS was 11.10 months for devimistat plus mFFX versus 11.73 months for FFX (hazard ratio [HR], 0.95 [95% CI, 0.77 to 1.18]; P = .655) and median progression-free survival was 7.8 months versus 8.0 months, respectively (HR, 0.99 [95% CI, 0.76 to 1.29]; P = .94). Grade ≥3 treatment-emergent adverse events with >10% frequency in the devimistat plus mFFX arm versus the FFX arm were neutropenia (29.0% v 34.5%), diarrhea (11.2% v 19.6%), hypokalemia (13.1% v 14.9%), anemia (13.9% v 13.6%), thrombocytopenia (11.6% v 13.6%), and fatigue (10.8% v 11.5%), respectively., Conclusion: Devimistat in combination with mFFX did not improve long- and short-term mPC patient outcomes compared with standard FFX. There were no new toxicity signals with the addition of devimistat.

Published
2024
Full Text
View/download PDF

41. Blockade of IL-1β and PD-1 with combination chemotherapy reduces systemic myeloid suppression in metastatic pancreatic cancer with heterogeneous effects in the tumor.

Author

Oberstein PE, Dias Costa A, Kawaler EA, Cardot-Ruffino V, Rahma OE, Beri N, Singh H, Abrams TA, Biller LH, Cleary J, Enzinger P, Huffman BM, McCleary NJ, Perez KJ, Rubinson DA, Schlechter BL, Surana R, Yurgelun MB, Wang SJ, Remland J, Brais LK, Bollenrucher N, Chang E, Ali LR, Lenehan PJ, Dolgalev I, Werba G, Lima C, Keheler CE, Sullivan KM, Dougan M, Hajdu C, Dajee M, Pelletier MR, Nazeer S, Squires M, Bar-Sagi D, Wolpin BM, Nowak JA, Simeone DM, and Dougan SK

Abstract

Innate inflammation promotes tumor development, although the role of innate inflammatory cytokines in established human tumors is unclear. Here we report clinical and translational results from a phase Ib trial testing whether IL-1β blockade in human pancreatic cancer would alleviate myeloid immunosuppression and reveal antitumor T-cell responses to PD-1 blockade. Patients with treatment-naïve advanced pancreatic ductal adenocarcinoma (n=10) were treated with canakinumab, a high-affinity monoclonal human anti-interleukin-1β (IL-1β), the PD-1 blocking antibody spartalizumab, and gemcitabine/n(ab)paclitaxel. Analysis of paired peripheral blood from patients in the trial versus patients receiving multiagent chemotherapy showed a modest increase in HLA-DR+CD38+ activated CD8+ T cells and a decrease in circulating monocytic myeloid-derived suppressor cells (MDSCs) by flow cytometry for patients in the trial, but not in controls. Similarly, we used patient serum to differentiate monocytic MDSCs in vitro and showed that functional inhibition of T-cell proliferation was reduced when using on-treatment serum samples from patients in the trial but not when using serum from patients treated with chemotherapy alone. Within the tumor we observed few changes in suppressive myeloid-cell populations or activated T cells as assessed by single-cell transcriptional profiling or multiplex immunofluorescence, although increases in CD8+ T cells suggest that improvements in the tumor immune microenvironment might be revealed by a larger study. Overall, the data indicate that exposure to PD-1 and IL-1β blockade induced a modest reactivation of peripheral CD8+ T cells and decreased circulating monocytic MDSCs; however, these changes did not lead to similarly uniform alterations in the tumor microenvironment.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results